Table 1. Studies on association between biologic therapy and 30-day postoperative morbidity after total proctocolectomy and IPAA for UC.
| Author | Year of publication | Study design | Biologic medication | Patient numbers (biologics/no biologics) | Infectious complication rate (%, biologics/no biologics) |
p -Value | AL rate (%, biologics/no biologics) |
p -Value | Pelvic sepsis rate (%, biologics/no biologics) |
p -Value |
|---|---|---|---|---|---|---|---|---|---|---|
| Selvasekar et al 42 | 2007 | RC | IFX | 47/254 | 28/10 | < 0.01 | 9/2 | 0.02 | 11/5 | NS |
| Mor et al 43a | 2008 | RC | IFX | 46/46 | NR | — | 17.4/2.2 | 0.023 | 21.7/2.2 | 0.016 |
| Coquet-Reinier et al 44 | 2010 | RCM | IFX | 13/13 | NR | — | 0/7.7 | NS | 7.7/0 | NS |
| Gainsbury et al 45 | 2011 | RC | IFX | 29/52 | 17.2/26.9 | NS | 3.5/9.6 | NS | 13.8/13.5 | NS |
| Selvaggi et al 46 | 2015 | MA | IFX | 162/468 | 26/8 | < 0.00001 | NR | — | NR | — |
| Kim et al 47 | 2020 | RCM | VDB | 25/54 | 8/20 | NS | NR | — | 4/0 | NS |
Abbreviations: AL, anastomotic leak; IFX, infliximab; IPAA, ileal pouch-anal anastomosis; MA, meta-analysis; NR, not reported; NS, not significant; RC, retrospective cohort study; RCM, retrospective case-matched study; UC, ulcerative colitis; VDB, vedolizumab.
a
Also included patients with indeterminate colitis.